Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Gastroenterology

Long-Term Complications and Cancer Risk

At a Glance

Chronic pancreatitis can damage insulin- and glucagon-producing cells, causing Type 3c diabetes with unpredictable blood sugar and severe lows. It also raises pancreatic cancer risk, but routine surveillance is usually reserved for people with hereditary risk or a formally defined family history.

As chronic pancreatitis (CP) progresses, it can lead to complications that affect your whole body. Two of the most significant long-term concerns are the development of a unique form of diabetes and an increased risk of pancreatic cancer. Understanding these risks allows you and your care team to monitor your health proactively.

Type 3c Diabetes: Blood-Sugar Variability and Hypoglycemia

When chronic inflammation and scarring damage the parts of the pancreas that produce hormones, a specific condition called Type 3c Diabetes (or pancreatogenic diabetes) can develop [1]. This is often misdiagnosed as Type 2 diabetes, but it behaves differently [2][3]. Diagnosis requires clinical context, as there is no single universally accepted test.

How Type 3c Differs

In Type 1 or Type 2 diabetes, the primary issue is the loss of insulin or the body’s inability to use it [4]. In Type 3c, the entire “endocrine neighborhood” can be damaged [5]:

  • Loss of Insulin: Like other forms of diabetes, your beta cells may no longer produce enough insulin to lower your blood sugar [5].
  • Loss of Glucagon: Unlike other types, Type 3c also involves damage to alpha cells, which produce glucagon—the hormone that raises your blood sugar when it gets too low [5][6].
  • Glycemic Variability: Because you are missing both the “brake” (insulin) and the “gas pedal” (glucagon) for blood sugar, your levels can swing rapidly [7][8].
  • Severe Hypoglycemia: Without adequate glucagon to protect you, you can be at a much higher risk for sudden, prolonged episodes of low blood sugar (hypoglycemia), especially at night [8][9].

Management Strategies

Because of its unpredictable nature, doctors often recommend Continuous Glucose Monitoring (CGM) as a shared decision, particularly for insulin-treated patients [10]. A CGM provides real-time data and alerts you to “lows” before they become emergencies [10]. You should also have a concrete hypoglycemia action plan, including fast carbohydrate treatment and a clinician-prescribed rescue glucagon [11]. While metformin may be used in mild cases, many patients eventually require a basal-bolus insulin approach, managed carefully to avoid crashes [11][12].

Assessing Pancreatic Cancer Risk

Having chronic pancreatitis does increase the long-term risk of developing pancreatic cancer compared to the general population [13]. While most people with nonhereditary CP do not develop pancreatic cancer, certain factors can significantly raise that risk, and understanding them is important for your care plan [14][15].

Key Risk Factors

  • Hereditary Factors: Individuals with hereditary pancreatitis (such as specific pathogenic PRSS1 variants) or a strong family history of pancreatic cancer have a significantly higher lifetime risk [13][16].
  • Smoking: Tobacco use is a powerful “multiplier” that significantly increases cancer risk and worsens overall disease [14][17].
  • Duration of Disease: The risk tends to increase the longer you have lived with chronic inflammation [13].
  • New-Onset Diabetes: If your diabetes suddenly appears or becomes much harder to control after years of stability, it can sometimes be a non-specific clinical sign requiring medical review to evaluate for a new growth in the pancreas rather than just a complication of CP [18][19][20].

Surveillance and Screening

Not every patient with CP needs routine cancer screening. Routine pancreatic cancer surveillance is generally not recommended for ordinary sporadic or alcohol-related CP [21][22].

  • Who is Screened?: Surveillance is strongly recommended for those with pathogenic syndromes (like PRSS1) and those with a formally defined family history of pancreatic cancer [21][22].
  • When to Start: For high-risk individuals, screening typically begins at an age determined by their specific syndrome and family history, and is performed at specialized pancreas centers [21][22].
  • The Methods: The preferred tools for screening involve Magnetic Resonance Imaging (MRI/MRCP) and Endoscopic Ultrasound (EUS), with the starting age and interval determined by a high-risk pancreas program [22][23]. Watching for “alarm symptoms” like jaundice or weight loss is diagnostic evaluation, not an effective substitute for a validated screening program.

Summary of Risks and Monitoring

Condition Primary Concern Screening/Monitoring
Type 3c Diabetes Blood-sugar variability; severe lows Annual HbA1c; CGM for insulin users [11][10]
Hereditary CP (PRSS1) High lifetime cancer risk MRI/EUS determined by high-risk program [21][22]
General CP Moderate cancer risk increase Monitoring for “alarm” symptoms (jaundice, weight loss) [20]
Lifestyle Factors Increased inflammation and cancer risk Smoking and alcohol cessation [14][20]

Common questions in this guide

What is Type 3c diabetes, and how is it linked to chronic pancreatitis?
Type 3c diabetes, also called pancreatogenic diabetes, can develop when chronic pancreatitis damages the pancreas's insulin- and glucagon-producing cells. Because both hormones may be reduced, blood sugar can swing quickly and the condition may not behave like typical Type 2 diabetes.
Why can chronic pancreatitis cause dangerous low blood sugar?
Damage to the pancreas may reduce glucagon, a hormone that normally raises blood sugar when it falls too low. This can make hypoglycemia sudden or prolonged, especially at night, so ask your clinician about glucose monitoring, fast carbohydrates, and a prescribed rescue glucagon plan.
Should everyone with chronic pancreatitis have pancreatic cancer screening?
No. Routine surveillance is generally not recommended for ordinary sporadic or alcohol-related chronic pancreatitis, while people with hereditary pancreatitis such as pathogenic PRSS1 variants or a formally defined family history may need a high-risk program. Specialists commonly use MRI/MRCP or endoscopic ultrasound, with timing based on individual risk.
Does chronic pancreatitis increase pancreatic cancer risk?
Chronic pancreatitis increases pancreatic cancer risk compared with the general population, but most people with nonhereditary chronic pancreatitis do not develop pancreatic cancer. Risk is higher with hereditary pancreatitis, a strong family history, tobacco use, and longer disease duration.
What should I do if my diabetes suddenly becomes harder to control?
Contact your clinician for prompt review rather than assuming it is only a routine change in diabetes. New-onset diabetes or a sudden change after years of stability can be a nonspecific warning sign, and your clinician may consider updated pancreatic imaging or other evaluation.
Can a continuous glucose monitor help with Type 3c diabetes?
A CGM can show real-time glucose changes and provide alerts for low levels, which may be useful for insulin-treated people with Type 3c diabetes. It is a shared decision with your clinician and does not replace a plan for treating hypoglycemia.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Should we test my C-peptide or pancreatic polypeptide levels to help evaluate my pancreatic function and diabetes status?
  2. 2.Am I a candidate for continuous glucose monitoring (CGM) to help manage my blood sugar variability and detect overnight hypoglycemia?
  3. 3.Does my current medication plan, including insulin or metformin, account for the fact that my body may not produce enough glucagon to recover from 'lows'?
  4. 4.Given my diagnosis of chronic pancreatitis, what is my specific risk for pancreatic cancer based on my genetics, smoking history, and the duration of my disease?
  5. 5.Should I be enrolled in a formal surveillance program with annual MRIs or endoscopic ultrasounds (EUS) at a specialized pancreas center based on my risk profile?
  6. 6.If my diabetes suddenly becomes much harder to control, is that a reason to order new imaging to check for changes in my pancreas?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (23)
  1. 1

    Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer.

    Hart PA, Bellin MD, Andersen DK, et al.

    The lancet. Gastroenterology & hepatology 2016; (1(3)):226-237 doi:10.1016/S2468-1253(16)30106-6.

    PMID: 28404095
  2. 2

    DIAGNOSIS OF ENDOCRINE DISEASE: Diagnosing and classifying diabetes in diseases of the exocrine pancreas.

    Petrov MS, Basina M

    European journal of endocrinology 2021; (184(4)):R151-R163.

    PMID: 33460395
  3. 3

    Distinguishing exocrine pancreas disease-associated diabetes from type 2 diabetes based on anthropometric and metabolic parameters.

    Juza A, Kołodziej-Spirodek L, Gutkowski K, et al.

    World journal of diabetes 2025; (16(2)):95102 doi:10.4239/wjd.v16.i2.95102.

    PMID: 39959260
  4. 4

    Diagnosis and risk factors in pancreatogenic diabetes.

    Sharma RK, Singh A, Dawra S

    Advances in clinical chemistry 2026; (131()):177-193 doi:10.1016/bs.acc.2025.10.003.

    PMID: 41708204
  5. 5

    Autoimmunity May Explain Diabetes in a Subset of Patients With Recurrent Acute and Chronic Pancreatitis: A Pilot Study.

    Yadav D, Whitcomb DC, Tang G, et al.

    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2023; (21(1)):226-228.e1 doi:10.1016/j.cgh.2021.11.011.

    PMID: 34793964
  6. 6

    Defects in α-Cell Function in Patients With Diabetes Due to Chronic Pancreatitis Compared With Patients With Type 2 Diabetes and Healthy Individuals.

    Mumme L, Breuer TGK, Rohrer S, et al.

    Diabetes care 2017; (40(10)):1314-1322 doi:10.2337/dc17-0792.

    PMID: 28751547
  7. 7

    Increased Glycemic Variability in Patients With Chronic Pancreatitis and Diabetes Compared to Type 2 Diabetes.

    Davidsen L, Jensen MH, Kronborg T, et al.

    Journal of diabetes science and technology 2025; 19322968251356239 doi:10.1177/19322968251356239.

    PMID: 40682262
  8. 8

    Continuous Glucose Monitoring for the Detection of Hypoglycemia in Patients With Diabetes of the Exocrine Pancreas.

    Shivaprasad C, Gautham K, Shah K, et al.

    Journal of diabetes science and technology 2021; (15(6)):1313-1319 doi:10.1177/1932296820974748.

    PMID: 33322930
  9. 9

    Glycemic variability in chronic calcific pancreatitis with diabetes mellitus and its possible determinants.

    Chowdhury AS, Palui R, Pramanik S, Mondal S

    Diabetes & metabolic syndrome 2024; (18(8)):103100 doi:10.1016/j.dsx.2024.103100.

    PMID: 39142092
  10. 10

    Efficacy and safety of continuous glucose monitoring on glycaemic control in patients with chronic pancreatitis and insulin-treated diabetes: A randomised, open-label, crossover trial.

    Davidsen L, Cichosz SL, Stæhr PB, et al.

    Diabetes, obesity & metabolism 2025; (27(6)):3379-3388 doi:10.1111/dom.16356.

    PMID: 40099620
  11. 11

    Chronic Pancreatitis and Diabetes Mellitus.

    Lin YK, Johnston PC, Arce K, Hatipoglu BA

    Current treatment options in gastroenterology 2015; (13(3)):319-31 doi:10.1007/s11938-015-0055-x.

    PMID: 26084759
  12. 12

    Type 3c diabetes associated with chronic pancreatitis: A narrative review.

    Rasheed A, Galande S, Farheen S, et al.

    Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 2025; (25(7)):1003-1012 doi:10.1016/j.pan.2025.08.005.

    PMID: 40819996
  13. 13

    Chronic Pancreatitis Is a Risk Factor for Pancreatic Cancer, and Incidence Increases With Duration of Disease: A Systematic Review and Meta-analysis.

    Gandhi S, de la Fuente J, Murad MH, Majumder S

    Clinical and translational gastroenterology 2022; (13(3)):e00463 doi:10.14309/ctg.0000000000000463.

    PMID: 35142721
  14. 14

    Incidence of and risk factors for pancreatic cancer in chronic pancreatitis: A cohort of 1656 patients.

    Hao L, Zeng XP, Xin L, et al.

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2017; (49(11)):1249-1256 doi:10.1016/j.dld.2017.07.001.

    PMID: 28756974
  15. 15

    Incidence and risk of pancreatic cancer in patients with chronic pancreatitis: defining the optimal subgroup for surveillance.

    Kim HS, Gweon TG, Park SH, et al.

    Scientific reports 2023; (13(1)):106 doi:10.1038/s41598-022-26411-8.

    PMID: 36596818
  16. 16

    Hereditary Pancreatitis in the United States: Survival and Rates of Pancreatic Cancer.

    Shelton CA, Umapathy C, Stello K, et al.

    The American journal of gastroenterology 2018; (113(9)):1376 doi:10.1038/s41395-018-0194-5.

    PMID: 30018304
  17. 17

    Chronic Pancreatitis and Pancreatic Cancer Risk: A Systematic Review and Meta-analysis.

    Kirkegård J, Mortensen FV, Cronin-Fenton D

    The American journal of gastroenterology 2017; (112(9)):1366-1372 doi:10.1038/ajg.2017.218.

    PMID: 28762376
  18. 18

    Effects of Pancreatitis and Type 2 Diabetes Mellitus on the Development of Pancreatic Cancer: A Nationwide Nested Case-Control Study.

    Kim YE, Yu MH, Nam CM, Kang ES

    Diabetes & metabolism journal 2025; (49(2)):252-263 doi:10.4093/dmj.2024.0277.

    PMID: 40073907
  19. 19

    Risk of pancreatic cancer in patients undergoing surgery for chronic pancreatitis.

    Zheng Z, Chen Y, Tan C, et al.

    BMC surgery 2019; (19(1)):83 doi:10.1186/s12893-019-0537-1.

    PMID: 31286902
  20. 20

    Pancreatic Cancer in Chronic Pancreatitis: Pathogenesis and Diagnostic Approach.

    Le Cosquer G, Maulat C, Bournet B, et al.

    Cancers 2023; (15(3)) doi:10.3390/cancers15030761.

    PMID: 36765725
  21. 21

    International consensus guidelines on surveillance for pancreatic cancer in chronic pancreatitis. Recommendations from the working group for the international consensus guidelines for chronic pancreatitis in collaboration with the International Association of Pancreatology, the American Pancreatic Association, the Japan Pancreas Society, and European Pancreatic Club.

    Greenhalf W, Lévy P, Gress T, et al.

    Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 2020; (20(5)):910-918 doi:10.1016/j.pan.2020.05.011.

    PMID: 32624419
  22. 22

    AGA Clinical Practice Update on Pancreas Cancer Screening in High-Risk Individuals: Expert Review.

    Aslanian HR, Lee JH, Canto MI

    Gastroenterology 2020; (159(1)):358-362 doi:10.1053/j.gastro.2020.03.088.

    PMID: 32416142
  23. 23

    Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium.

    Goggins M, Overbeek KA, Brand R, et al.

    Gut 2020; (69(1)):7-17 doi:10.1136/gutjnl-2019-319352.

    PMID: 31672839

This page is for informational purposes only and does not constitute medical advice. Decisions about Type 3c diabetes management, cancer surveillance, imaging, and medication changes should be made with your gastroenterology or diabetes care team.

Get notified when new evidence is published on chronic pancreatitis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.